Inorbit Therapeutics Overview
- Year Founded
-
2015
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Liquidation
Inorbit Therapeutics General Information
Description
Operator of a drug discovery and development company intended to mitigate the risk of drug-induced liver injury. The company focuses on the discovery and development of novel therapies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, enabling patients to improve their health conditions caused due to drug failure.
Contact Information
Website
www.inorbittx.comCorporate Office
- Pepparedsleden 1
- 431 83 Molndal
- Sweden
Corporate Office
- Pepparedsleden 1
- 431 83 Molndal
- Sweden
Inorbit Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Bankruptcy: Liquidation | 05-Nov-2024 | Completed | Bankruptcy: Liquidation | |||
| 4. Later Stage VC | Completed | Clinical Trials - Phase 1 | ||||
| 3. Early Stage VC | Cancelled | Clinical Trials - Phase 1 | ||||
| 2. Grant | 15-Nov-2018 | $33.1K | Completed | Clinical Trials - Phase 1 | ||
| 1. Early Stage VC | 01-Jan-2017 | Completed | Clinical Trials - Phase 1 |
Inorbit Therapeutics Comparisons
Industry
Financing
Details
Inorbit Therapeutics Competitors (2)
One of Inorbit Therapeutics’s 2 competitors is Intercept Pharmaceuticals, a Formerly VC-backed company based in Morristown, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA |
Inorbit Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Inorbit Therapeutics Patents
Inorbit Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202001856-D0 | Compounds useful in inhibiting ketohexokinase and methods of making and using the same | Inactive | 11-Feb-2020 | ||
| CA-3167812-A1 | Compounds useful in inhibiting ketohexokinase and methods of making and using the same | Pending | 11-Feb-2020 | ||
| US-20230096663-A1 | Farnesoid x receptor modulating compounds and methods of using the same | Pending | 11-Feb-2020 | ||
| EP-4106762-A1 | Compounds useful in inhibiting ketohexokinase and methods of making and using the same | Inactive | 11-Feb-2020 | ||
| AU-2021219332-A1 | Compounds useful in inhibiting ketohexokinase and methods of making and using the same | Inactive | 11-Feb-2020 | C07D417/14 |
Inorbit Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Inorbit Therapeutics FAQs
-
When was Inorbit Therapeutics founded?
Inorbit Therapeutics was founded in 2015.
-
Where is Inorbit Therapeutics headquartered?
Inorbit Therapeutics is headquartered in Molndal, Sweden.
-
What is the size of Inorbit Therapeutics?
Inorbit Therapeutics has 3 total employees.
-
What industry is Inorbit Therapeutics in?
Inorbit Therapeutics’s primary industry is Drug Discovery.
-
Is Inorbit Therapeutics a private or public company?
Inorbit Therapeutics is a Private company.
-
What is Inorbit Therapeutics’s current revenue?
The current revenue for Inorbit Therapeutics is .
-
Who are Inorbit Therapeutics’s competitors?
Intercept Pharmaceuticals and Gilead Sciences are competitors of Inorbit Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
